Blue Cross wins dismissal of US claims over spinal fusion treatment
MLex Summary: TranS1’s US antitrust complaint against Blue Cross Blue Shield must be dismissed because of the lack of clarity in the definition of the product market and TranS1’s role, according...To view the full article, register now.
Already a subscriber? Click here to view full article